Production of Diagnostic and Therapeutic Radionuclides with Uranium and Thorium Molten Salt Fuel Cycles

Targeted radionuclide therapy (TRT) is an innovative and flexible approach for treating various forms of cancer, enabling selective delivery of cytotoxic radiation to cancerous cells while minimizing damage to healthy tissue. Although TRT has proven to be highly promising for treating even advanced-stage cancers, ensuring a stable supply of the radionuclides essential for its use remains a significant challenge today. This is also true for radionuclides utilized in nuclear imaging procedures, such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT). Liquid-fueled molten salt reactors (MSRs) are promising for producing large quantities of highly desirable radionuclides for imaging and therapy, offering the ability to recover these radionuclides online without the need for interruptions to power production. In this study, the production of numerous beta- and alpha-emitting radionuclides for use in TRT and diagnostic procedures was studied in two small, geometrically identical, thermal spectrum MSR models—one operating with LEU fuel, and the other with a mixture of HALEU and thorium—using a novel MSR refueling and waste management concept. For therapeutic alpha emitters such as 225Ac and 213Bi, the impact of thorium utilization on production yields was significant, facilitating greatly increased production.